Ablynx N.v.

Bayer Intellectual Property Gmbh

Bayer Healthcare Aktiengesellschaft

Özkan Yalkinoglu

Josefin-Beate Holz

Steven De Bruyn

Stefaan Rossenu

Karl-Heinz Schlemmer

Adrian Tersteegen

Jörg Keldenich

Martin Hendrix

Dagmar Karthaus

Frank Mauler

Denis Francois Hochstrasser

Arno Friedl

Jean-Charles Sanchez

Maria Niewöhner, Legal Representative

Irene Gerlach

Volker Hinz

Maria Laura Sargentini-Maier

Maria-Laura Sargentini-Maier

David Brückner

Gerhard König

Odile Carrette

Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.

Method for treating rheumatoid arthritis by administering IL-6 receptor antibodies

Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies

A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.

Biomarkers for diagnosing alzheimer's disease

The invention relates to new substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia.

Substituted imidazotriazines

Growing community of inventors

Wuppertal, Germany

Özkan Yalkinoglu